Vasopressin: Its current role in anesthetic practice

Jayanta K. Mitra, Jayeeta Roy¹, Saikat Sengupta²

Abstract

Vasopressin or antidiuretic hormone is a potent endogenous hormone, which is responsible for regulating plasma osmolality and volume. In high concentrations, it also raises blood pressure by inducing moderate vasoconstriction. It acts as a neurotransmitter in the brain to control circadian rhythm, thermoregulation and adrenocorticotropic hormone release. The therapeutic use of vasopressin has become increasingly important in the critical care environment in the management of cranial diabetes insipidus, bleeding abnormalities, esophageal variceal hemorrhage, asystolic cardiac arrest and septic shock. After 10 years of ongoing research, vasopressin has grown to a potential component as a vasopressor agent of the anesthesiologist’s armamentarium in the treatment of cardiac arrest and severe shock states.

Keywords: Cardiopulmonary resuscitation, hemorrhagic shock, operating room, septic shock, vasopressin

Introduction

Vasopressin is a potent vasopressor that may be a useful therapeutic agent in the treatment of cardiac arrest, septic and several other shock states and esophageal variceal hemorrhage. Studies indicate that the use of vasopressin during cardiopulmonary resuscitation may improve the survival of patients with asystolic cardiac arrest.¹ Vasopressin deficiency can contribute to refractory shock states associated with sepsis, hypovolemia, cardiogenic shock and cardiac arrest. Low doses of vasopressin can restore vasomotor tone in conditions that are resistant to catecholamines, with preservation of renal blood flow and urine output. It may also be useful in reducing bleeding and mortality associated with esophageal variceal hemorrhage. Terlipressin is a useful vasopressin analog that produces sustained increases in blood pressure in septic patients.

Physiology

Vasopressin is a nonapeptide synthesized as a prohormone in magnocellular neuron cell bodies of the paraventricular and supraoptic nuclei of the posterior hypothalamus. It is bound to a carrier protein, neurohypophysin, and transported along the supraoptic hypophyseal tract to the axonal terminals of magnocellular neurons located in the posterior pituitary. Synthesis, transport and storage take 1-2 hours. Normal plasma concentrations are < 4 pg/ml. It has a half-life of 10-35 minutes, being metabolised by vasopressinases. Vasopressin acts on V1, V2, V3 and oxytocin-type receptors (OTR).

V1 vascular receptors mediate vasoconstriction and are located on vascular smooth muscle. V1 receptors are found in the kidney, myometrium, bladder, hepatocytes, platelets, adipocytes and spleen. These G-protein coupled receptors activate phospholipase-C via Gq G-protein, which ultimately leads to an increase in intracellular calcium.

V2 receptors are predominantly located in the distal tubule and collecting ducts of the kidney. These G-protein coupled receptors activate adenyl cyclase to increase cyclic adenosine monophosphate. This
mobilizes aquaporin channels, which are inserted into the apical membrane of the renal collecting duct cells and endothelial cells. V2 receptors are responsible for antidiuretic effects of vasopressin. Their presence on endothelial cells induces the release of Von Willebrand Factor (VWF) and Factor VII: Coagulant (FVII: c). VWF protects FVII from breakdown in plasma and is important in binding platelets to the site of bleeding.

V3 receptors are found mainly in the pituitary. They are Gq-coupled G-protein receptors, which increase intracellular calcium when activated. They are thought to be involved in adrenocorticotropic hormone release, responsible for the actions of vasopressin on the central nervous system, and may act as a neurotransmitter or mediator involved with memory consolidation or retrieval and body temperature regulation.[2]

Vasopressin has equal affinity for OTR as oxytocin. Activation of these receptors raises intracellular calcium via the phospholipase C and phosphoinositide pathway. They are found predominantly on myometrium and vascular smooth muscle. In addition, they are located on vascular endothelial cells where they increase endothelial nitric oxide synthase activity, increasing nitric oxide, which is a potent vasodilator. It is postulated that OTR placement on vascular endothelium and their subsequent activation may account for vasopressin’s selective response on different vascular beds.

The most potent stimulus for vasopressin release is an increased plasma osmolarity and severe hypovolemia.[3] Central nervous input mediated by pain, stress, nausea, hypoxia, pharyngeal stimuli and endogenous and exogenous chemical mediators also increase vasopressin release.

Hyperosmolarity is sensed by both central and peripheral osmoreceptors. Central osmoreceptors (subfornical organ nuclei) located outside the blood-brain barrier monitor systemic plasma osmolality. Peripheral osmoreceptors are found in the portal veins and give early warning of ingested food and fluid osmolarity. Signals are transmitted via the vagus to the nucleus tractus solitaries, area postrema and ventrolateral medulla and finally to the paraventricular nuclei and supraoptic nuclei where vasopressin is manufactured in the magnocellular neuron cell bodies. Osmolarity is finely controlled in the range of 275-290 mOsm/kg.

Plasma volume and the resultant change in arterial pressure are less sensitive controllers of vasopressin release. A 20-30% reduction in mean arterial pressure (MAP) is needed to induce a response. An 8-10% reduction in plasma volume detected by arterial stretch receptors is required to induce an exponential increase in vasopressin release. A reduction in plasma volume increases the sensitivity of the osmoreceptors and vice versa. A decrease causes an increase in plasma norepinephrine and renin concentrations whereas the plasma vasopressin concentration does not increase until MAP decreases.

Acetylcholine, histamine, dopamine, prostaglandins, angiotensin and other catecholamines directly stimulate vasopressin release. High PaCO₂ stimulate carotid body chemoreceptors and thus increase vasopressin levels. Opioids, γ-aminobutyric acid and atrial natriuretic peptide inhibit vasopressin by α1-adrenoreceptors whereas the α2-adrenoreceptors and β-adrenergic receptors inhibit vasopressin and oxytocin release.

A very similar substance, lysine vasopressin (LVP) or lypressin, has the same function in pigs and is often used in human therapy. Terlipressin (triglycyl–lysine vasopressin) became popular in 1990s because it has a prolonged duration of action. It is a prodrug and is converted to the lysine vasopressin in the circulation after the N-triglycyl residue is cleaved by endothelial peptidases. This results in a slow release of the vasoactive LVP. Ornipressin is a derivative of arginine vasopressin acting specifically on the V1 subtype receptors. In other words, it is a derivative that mimics the effects of arginine vasopressin on vascular smooth muscle; however, it has no antidiuretic effect. Desmopressin acetate (1-deamino-8-D-arginine vasopressin or dDAVP) is a synthetic analog of the antidiuretic hormone arginine vasopressin that was initially devoted to the treatment of central diabetes insipidus. Through a direct action on endothelial V2 receptors, desmopressin raises factor VIII and VWF plasma concentrations in healthy volunteers. The increase in VWF concentrations is related to a release from endothelial intracellular storage sites and not to de novo synthesis. Thus, this effect is rapid, transient and diminishes with repeated injections at short intervals (tachyphylaxis). This agent also transiently increases t-PA and prostacyclin plasma levels. It has additional but unclear effects on hemostasis.[4]

**Pharmacology**

Exogenous vasopressin (8 arginine vasopressin) is presented as sterile aqueous solution of synthetic vasopressin for intravenous, intramuscular and subcutaneous administration. It is not protein-bound and has a volume of distribution of 140 ml/kg. The plasma half-life of vasopressin is 24 minute. It is cleared by renal elimination (65%) and metabolism (35%) by tissue peptidase.
**Therapeutic Use**

**Septic shock**

In septic shock there are biphasic changes in vasopressin concentration with high concentration in the early part to maintain organ perfusion, but as the shock state progresses the concentrations decrease. Possible explanations include exhaustion of stores and autonomic nervous system dysfunction. Large doses of norepinephrine are inhibitory to vasopressin release. Dünser and colleagues published the largest randomized prospective controlled study in 2003. In this study 48 patients with catecholamine resistant vasodilatory shock were prospectively randomized to receive a combined infusion of vasopressin 4 IU/hour and norepinephrine or norepinephrine alone to maintain a MAP above 70 mmHg. The vasopressin group showed a significant increase in MAP, cardiac index, systemic vascular resistance index and left ventricular stroke work index as well as reduced norepinephrine requirements and heart rates. Compared with norepinephrine group, there was better preservation of gut mucosal blood flow and a significantly less incidence of tachyarrhythmia’s. The vasopressin and septic shock trial (VASST) was the first multicenter, blinded, randomized trial comparing low-dose vasopressin with norepinephrine in 778 patients with septic shock. The use of vasopressin did not reduce mortality but was shown to be as safe as norepinephrine.

After cardiovascular function has stabilized and norepinephrine support could be withdrawn to dosages <0.2–0.3 μg/kg/min, vasopressin was slowly withdrawn in most studies. Administered as a supplementary vasopressor agent, vasopressin seems to be capable of bridging the phase of advanced cardiovascular failure and preventing a vicious cycle of high-dose catecholamine therapy that may develop. The pivotal issue of clinical research on the use of vasopressin in septic shock must therefore not be the question ‘Can vasopressin replace norepinephrine therapy?’ but be the question ‘Can the supplementary infusion of vasopressin in addition to norepinephrine improve the quantitative and qualitative outcome of advanced septic shock?’

Since low vasopressin plasma concentrations have been found in septic shock patients, vasopressin infusion was first proposed as hormone replacement therapy rather than vasopressor therapy. A recent study demonstrated that plasma vasopressin levels were almost always increased in the initial phase of septic shock, and decreased thereafter. Accordingly, the relative vasopressin deficiency and consequently the suggested indication for vasopressin hormone replacement was found only in one-third of late septic shock patients. Additionally, the increase in arterial pressure during vasopressin infusion occurs independently of plasma vasopressin concentrations. Vasopressin therapy at dosages from 0.01 to 0.1 U/min increases plasma concentrations to 100–250 pg/ml, which is 50-fold to 100-fold higher than the vasopressin levels reported in patients with cardiogenic shock and septic shock states who still respond to conventional therapy. Therefore, institution of vasopressin infusion in advanced septic shock should not be guided by endocrinological, but by hemodynamic indications.

Whether the possibility of ‘bridging’ vasopressin with catecholamine therapy in advanced septic shock patients may have a benefit/risk ratio within a tolerable clinical range that may improve quantitative and qualitative patient outcome, can only be determined by a large, prospective, randomized study. Such a study will finally also answer the question of whether positive effects of vasopressin on macrocirculatory parameters are outweighed by possible adverse effects on the microcirculation system, the hepatosplanchnic system or the coagulation system. While no data of supplementary vasopressin infusion in advanced septic shock on patient outcome exists, the infusion of vasopressin in addition to catecholamine vasopressor agents in order to reduce high, potentially toxic adrenergic vasopressor dosages can only be recommended as a last-resort therapy.

**Hemorrhagic shock**

Vasopressin should be used at a dosage of 0.2-0.4 IU/kg bolus injection followed by 0.8 IU/kg/min continuous infusions depending on the severity of shock stage. Morales et al successfully treated two patients suffering from gastrointestinal hemorrhage and refractory hypovolemic shock with a vasopressin infusion of 0.001 and 0.004 IU/kg/min, respectively.

**Vasodilatory shock after cardiac surgery**

Comparable to septic shock vasodilatory shock after cardiac surgery is characterized by poor response of vascular smooth muscles to circulating catecholamines. A supplementary vasopressin infusion 0.6–6 U/hour has been repeatedly observed to reverse advanced vasodilatory shock in post cardiotomy patients, although some authors have advised caution with the use of vasopressin in cardiac surgery because of possible reductions in cardiac output.

A retrospective analysis in 41 postcardiotomy shock patients found improved myocardial performance during vasopressin therapy. Vasopressin given as a continuous infusion not exceeding 6 U/h proved to be...
devoid of adverse effects on the heart in these patients with catecholamine-resistant postcardiotomy shock. The observation of a significant reduction in heart rate, vasopressor and inotropic support even suggests a substantial improvement in myocardial performance. These findings are supported by the observation of a significant decrease of cardiac enzymes and the spontaneous cardioversion of tachyarrhythmia into sinus rhythm in nearly half of patients with new-onset tachyarrhythmia. Therefore, vasopressin may provide an important additional treatment option in patients receiving high vasopressor and inotropic support after cardiac surgery.\[^{14}\]

**Other vasodilatory shock states**

**Anaphylactic shock**

The predominant pathophysiological mechanisms of cardiovascular failure in anaphylactic shock are vasodilatation and hypovolemia resulting from increased endothelial permeability. All authors observed rapid hemodynamic stabilization after vasopressin bolus of 2-10 IU, followed by a continuous infusion of 40 IU over 60 min, in one report.\[^{15}\] Tsuda \textit{et al.}\[^{16}\] investigated the reversal of vascular relaxation induced by histamine in human internal mammary arteries, and found that epinephrine could only partly reverse histamine-induced vasodilatation, whereas vasopressin, methylene blue and drugs involved in the inhibition of nitric oxide and prostaglandin generation caused by a complete reversal of vascular relaxation.

**Hypotension during spinal or epidural anesthesia**

Supplementary opioids and \(\alpha\)-receptor agonist’s drugs are being frequently used during the administration of spinal/epidural block. These drugs inhibit endogenous vasopressin release. It was hypothesized that the administration of a vasopressin analog may mimic the physiological adaptation to sympathetic block induced by epidural anesthesia.\[^{17}\]

**Acute brain injury**

In view of systemic vasoconstrictive and local vasodilatory effects on arteries of the circle of Willis, vasopressin has also been used to ensure adequate cerebral perfusion pressure in the perioperative setting. Yeh \textit{et al.} reported on the successful administration of vasopressin (2.4IU/h) in a patient suffering from spontaneous cerebellar and subarachnoid hemorrhage with advanced vasodilatory shock, neurogenic pulmonary oedema, and myocardial dysfunction.\[^{18}\] Similarly, Bradley \textit{et al.}\[^{19}\] administered terlipressin (0.25 mg), a vasopressin analog with a pressor effect for approximately 4-6 h, in a hemodynamically unstable patient with subarachnoid hemorrhage.

Vasopressin is a safe adjunct vasopressor to phenylephrine for hypervolemic, hemodilutional, and hypertensive treatment in patients with subarachnoid hemorrhage. Vasopressin does not induce vasospasm or aggravate electrolyte disorders.\[^{20}\]

**Hormone replacement in brain-dead organ donors**

Vasopressin has been administered in brain-dead organ donors since 1986. The1 IU bolus followed by 0.5-4 IU/hr dose of vasopressin, not only treated diabetes insipidus, but resulted in significant reductions in vasopressor and inotropic drug requirements.\[^{21}\]

**Perioperative hypotension in pts chronically treated with ACE inhibitors**

As angiotensin II is a physiological stimulator of vasopressin release, perioperative hypotension in pts chronically treated with ACE inhibitors has been speculated to be caused by vasopressin deficiency. Studies showed that 1 mg terlipressin was effective in rapidly correcting refractory hypotension without major side-effects.\[^{22}\]

**Vasodilatory shock after pheochromocytoma extirpation**

In view of extensive adrenergic receptor downregulation, vasopressin therapy seems to be particularly beneficial if catecholamine resistant vasodilatory shock develops after pheochromocytoma surgery. Augoustides \textit{et al.} successfully applied AVP in patients with catecholamine resistant vasoplegic shock after the urgent resection of a massive pheochromocytoma.\[^{23}\]

**Hypotension caused by carcinoid crisis**

Vasopressin infusion has been reported to be an alternative to sympathomimetic vasoconstrictors, which are considered relatively contraindicated in pts with carcinoid tumors because they may exaggerate further peptide release via adrenergic receptor stimulation.\[^{24}\]

**Cardiac arrest (CPR)**

The use of epinephrine in resuscitation is universal, but there is little evidence to show that vasopressin improves survival in humans. Theoretically vasopressin is an attractive alternative to epinephrine during cardiopulmonary resuscitation because it significantly improves total cerebral and myocardial blood flow and causes a sustained increase in MAP compared with maximal dose of epinephrine.\[^{25}\] Wenzel and colleagues performed a multicenter randomized double-blinded trial in 1186 patients who had an out-of-hospital cardiac arrest.\[^{26}\] They were randomly...
assigned to receive either 40 IU of vasopressin or 1 mg of epinephrine during resuscitation. In the asystolic group, significantly more patients reached hospital who received vasopressin, compared with those who received epinephrine. 4.7% of the vasopressin group were discharged from the hospital compared with 1.5% in the epinephrine group. No difference was found between the groups in patients with pulse less electrical activity or ventricular fibrillation cardiac arrests. There is a suggestion that vasopressin may work better than epinephrine in hypoxemic, acidic conditions. It also suggests a better outcome in the vasopressin groups if there was delayed or prolonged resuscitation. In the contrary, another randomized control trial found that repeated doses of vasopressin during cardiac arrest did not improve survival rates compared with repeated doses of epinephrine.[27]

Because the effects of vasopressin have not been shown to differ from those of epinephrine in cardiac arrest, the current international guidelines for cardiopulmonary resuscitation (2010) recommended that 1 dose of vasopressin 40 units IV/IO may replace either the first or second dose of epinephrine in the treatment of cardiac arrest.

**Esophageal variceal bleeding**

Vasopressin acting via V1 receptors reduces portal blood flow, portal systemic collateral flow and variceal pressure. Its side-effects include increased peripheral resistance; reduced cardiac output and decreased coronary blood flow, which is reduced if combined with glyceryl trinitrate. A Cochrane review found that terlipressin; a prodrug of vasopressin produced a relative risk reduction in mortality from variceal hemorrhage of 34% compared with placebo.[28] The i.v. dose is 2 mg 4 hourly.

**Bleeding abnormalities**

Vasopressin acts via extrarenal V2 receptors to increase predominantly FVII: c and VWF. These actions are useful in certain types of Von Willebrand disease and mild forms of hemophilia. It can also be used in pts with impaired platelet function due to drugs such as aspirin or renal failure. The exact mechanism of its effect in these situations is not fully understood, but the increase in FVIII levels which allows activation of FX and the more efficient activation of platelets are all important.[29]

**Central diabetes insipidus**

Clinically, the patient produces vast quantities of dilute urine. Key feature is that urine osmolality is inappropriately low compared with plasma osmolality. Desmopressin (DDAVP) can reduce polyurea, nocturia and polydipsia in these patients.[30] It is given nasally, sublingually, i.m, or in critical care setting i.v.

**Adverse Effects/Safety**

Severe skin necrosis after extravasation of low-dose vasopressin administered for catecholamine resistant shock has been reported and peripheral administration of low-dose vasopressin infusions should be discouraged.[31] It is thrombogenic, acting via V2 receptors. Anaphylaxis, bronchospasm, urticaria and ischemia of the gastrointestinal tract have been reported with clinical use. Reduction in cardiac output and systemic oxygen delivery, impairment in gut mucosal and hepatic oxygenation, increases in aminotransferases activities and bilirubin concentrations and reduction in platelet count have also been observed. In addition, sodium concentration and plasma osmolality should be regularly evaluated, although to date there is no evidence that vasopressin analogs are linked to antidiuresis, water retention or renal impairment in septic shock patients. Conversely, several studies reported an improvement in renal function as well as advantages over sole catecholamine therapy in patients at risk for acute renal failure.

**Cost-effectiveness**

Cost is an issue, which might have limitations into ongoing studies on the use of vasopressin as an alternative to adrenaline as 1 ampoule (20 U) of vasopressin costs almost 70 times more than 1 ampoule of adrenaline. However, since vasopressin and epinephrine combined therapy improves the quality of life in patients of cardiopulmonary resuscitation,[32] it can be assumed that this would help in lowering the overall long-term cost in patient care in the combined therapy group compared against the hidden cost that would be needed for treatment and rehabilitation of long-term morbidity in the adrenaline group.

In a recent study by Stiell et al of in-hospital CPR, 87% of the patients in the vasopressin group also received epinephrine[32] and the usefulness of the combination regimen was demonstrated by clinical observations such as significantly improved coronary perfusion pressure,[33] increased likelihood of restoration of spontaneous circulation[34] and 24-hour survival rates.[35] No randomized control trials have yet been done to determine the cost-effectiveness of vasopressin.

**Future**

Clinical and experimental studies certainly support
the beneficial effects of low-dose vasopressin infusion in vasodilatory shock. Nevertheless, is an increase in arterial pressure, and perhaps in urine output, sufficient to support the use of vasopressin in all pts with septic shock? Although recent animal studies have suggested improved outcomes in animals treated with vasopressin, no clinical study including the VASST, has yet demonstrated reduced mortality in patients treated with vasopressin. Now, should vasopressin be considered as a vasopressor therapy, as endocrine support or both? In hypotensive septic shock, the catecholamine α1-adrenergic receptors may be desensitized or downregulated to standard catecholamine vasopressors, limiting their vasopressor activity. Because vasopressin binds to its own V1 vascular receptor, it can still act to restore vascular tone even if α1-receptors are downregulated. Vasopressin reduces catecholamine requirement, but there is no suggestion to use it as a conventional agent and titrated to arterial pressure. Rather it should be used at low fixed dosages. So, if we are using vasopressin more as endocrinological support, should we only be giving it to patients with low vasopressin concentrations? Sharshar and colleagues suggested that relative vasopressin deficiency occurred in only one-third of late septic shock patients. In addition, the effects of vasopressin on arterial pressure seem to occur regardless of the endogenous plasma vasopressin concentration. This observation suggests that vasopressin therapy may be beneficial in all patients with septic shock rather than only in those with low vasopressin concentration. Lin and colleagues recently proposed that a low vasopressin/norepinephrine ratio could predict the development of septic shock in emergency department patients with sepsis or severe sepsis, suggesting that the changes in vasopressin occur before shock develops, so vasopressin should perhaps be given early rather than as a last resort.

Vasopressin in combination with epinephrine can significantly increase hospital discharge rates in cardiac arrest victims. Vasopressin-catecholamine combination can improve hemodynamics in vasodilatory and hemorrhagic shock. However, its effects on patient outcome are yet to be established across the board. Nonetheless, in the perioperative setting vasopressin is being considered to be a potent adjunct vasopressor agent in advanced shock states that are unresponsive to conventional therapeutic strategies. More research is needed on the use of vasopressin, particularly in humans, to enable its full benefits as an alternative to adrenaline in cardiac arrest to be realized.

References
1. Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, Katsios N, Papastylionou A, Gkisioti S, et al. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. Arch Intern Med 2009;169:15-24.
2. Kam PC, Williams S, Young FF. Vasopressin and terlipressin: Pharmacology and its clinical relevance. Anaesthesia 2004;59:993-1001.
3. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979;236:F321-32.
4. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003;1:682-9.
5. Dünser MW, Mayr AJ, Ulmer H, Knotzer H, Sunann G, Pajk W, et al. Arginine vasopressin in advanced vasodilatory shock: A prospective randomized study. Circulation 2003;107:2313-9.
6. Russell-JA, Walley KR, Singer J, Gordon JC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:87-97.
7. Dobbs JK, Oliver JA, Landry DW. Vasopressin deficiency in the syndrome of irreversible sepsis. J Trauma 2003;54:149-54.
8. Sharshar T, Blanchard A, Puillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med 2003;31:1752-8.
9. Dünser MW, Hasibeder WR, Wenzel V, Schwarz S, Ulmer H, Knotzer H, et al. Endocrinologic response to vasopressin infusion in advanced vasodilatory shock. Crit Care Med 2004;32:1266-71.
10. Landry DW, Levin HR, Gallant EM, Ashton BC, Jr, See S, D’Alessandro D, et al. Vasopressin deficiency contributes to the vasodilatation of septic shock. Circulation 1997;95:1225-5.
11. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign Management Guidelines Committee: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:558-73.
12. Morales D, Madigan J, Cullinane S, Chen J, Heath M, Oz M, et al. Reversal of vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 1999;100:225-9.
13. Alffrig TN, Zimmerman MA, Selzman CH. Vasopressin in the cardiac surgery intensive care unit. Am J Crit Care 2002;11:326-32.
14. Dünser MW, Mayr AJ, Stallinger A, Ulmer H, Ritsch N, Knotzer H, et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med 2002;28:74-51.
15. Kill C, Wranze E, Wulf H. Successful treatment of severe anaphylactic shock with vasopressin. Int Arch Allergy Immunol 2004;134:243-9.
16. Tsuda A, Tanaka KA, Huraux C, Szlan F, Sato N, Yamaguchi K, et al. The in vitro reversal of histamine-induced vasodilatation in the human internal mammary artery. Anaesth Analg 2001;93:1453-9.
17. De Koek M, Laterre PF, Andruetto P, Vanderessen L, Dekron S, Vanderick B, et al. Ornipressin (Por 8): An efficient alternative to counteract hypotension during combined general/epidural anaesthesia. Anesth Analg 2000;90:1301-7.
18. Yeh CC, Wu CT, Lu CH, Yang CP, Wong CS. Early use of small dose vasopressin for unstable haemodynamics in an acute brain injury patient refractory to catecholamine treatment: A case report. Anaesth Analg 2003;97:577-9.
24. Veall GR, Peacock JE, Bux ND, Reilly CS. Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome. Br J Anaesth 1994;72:335-41.
25. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-82.
26. Wenzel V, Krismer AC, Arntz HR, Sitter H, Stadlbauer KH, Lindner KH. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 2004;350:105-13.
27. Mukoyama T, Kinoshiba K, Nagao K, Tanjish K. Reduced effectiveness of vasopressin in repeated doses for patients undergoing prolonged cardiopulmonary resuscitation. Resuscitation 2009;80:755-61.
28. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003;1:CD002147.
29. Ozgönenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin? Postgrad Med J 2007;83:159-63.
30. Tomita M, Stanhope R. Morbidity and mortality associated with vasopressin analogue treatment. J Pediatr Endocrinol Metab 2006;19:197-201.
31. Kahn JM, Kress JP, Hall JB. Skin necrosis after extracavitation of low-dose vasopressin administered for septic shock. Criti Care Med 2002;30:1899-901.
32. Stiell IG, Hébert PC, Wells GA, Vandemheen KL, Tang AS, Higginson LA, et al. Vasopressin versus epinephrine for in-hospital cardiac arrest: A randomised controlled trial. Lancet 2001;358:105-9.
33. Morris DC, Derezyk BE, Grzybowski M, Martin GB, Rivers EP, Wortsman J, et al. Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad Emerg Med 1997;4:878-83.
34. Lindner KH, Prengel JW, Brinkmann A, Strohmenger HU, Lindner IM, Lurie KG. Vasopressin administration in refractory cardiac arrest. Ann Intern Med 1996;124:1061-4.
35. Grmec S, Kamenik B, Mally S. Vasopressin in refractory out-of-hospital ventricular fibrillation: Preliminary results. Crit Care 2002;6:1P162.
36. Sharshar T, Anneau D. Endocrine effects of vasopressin in critically ill patients. Best Pract Res Clin Anaesthesiol 2008;22:265-73.
37. Liu Y, Ma HP, Lin AC, Cheng CF, Lin CM, Wang TL. Low plasma vasopressin/noradrenaline ratio predicts septic shock. Am J Emerg Med 2005;23:718-24.

How to cite this article: Mitra JK, Roy J, Sengupta S. Vasopressin: Its current role in anesthetic practice. Indian J Crit Care Med 2011;15:71-7.

Source of Support: Nil, Conflict of Interest: None declared.